
North America Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Country and Growth Forecast, 2023 -
Description
North America Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Country and Growth Forecast, 2023 - 2030
The North America Microbiome Diagnostics Market would witness market growth of 16.9% CAGR during the forecast period (2023-2030).
The US market dominated the North America Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $157,641.6 Thousands by 2030. The Canada market is exhibiting a CAGR of 19.5% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 19.1% during (2023 - 2030).
It is increasingly integrated into clinical practice, particularly in gastroenterology, oncology, immunology, dermatology, and women’s health. Clinicians utilize microbiome diagnostics to aid in disease diagnosis, risk assessment, treatment selection, and monitoring of therapeutic responses. For example, in gastroenterology, it helps identify microbial biomarkers associated with inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and colorectal cancer, guiding personalized treatment strategies and dietary interventions. In dermatology, it is used to study the skin microbiome and its role in dermatological conditions such as acne, eczema, and psoriasis, informing skincare interventions and therapeutic approaches. The adoption of microbiome diagnostics in clinical settings is driven by the need for more precise and personalized healthcare solutions tailored to individual patient characteristics and microbial profiles.
Additionally, it is widely utilized in research laboratories to investigate microbiome-host interactions, disease mechanisms, and therapeutic targets. Academic institutions, biotechnology companies, and pharmaceutical firms invest in microbiome research initiatives, leveraging microbiome diagnostics to drive innovation in drug discovery, biomarker identification, and therapeutic development. Researchers utilize microbiome diagnostics to study microbial communities’ composition, diversity, and function in various disease states, environmental contexts, and experimental models. It enables researchers to unravel the complex relationships between microbial communities and host physiology, paving the way for discoveries and breakthroughs in microbiome research.
Mexico’s pharmaceutical sector’s growth can provide financial resources and infrastructure support for clinical trials and research initiatives focused on microbiome-based interventions. The pharmaceutical sector in Mexico is divided into patented medicines, which represent 51 percent of the market by value, generics, which represent 35 percent, and over-the-counter products, which represent the remaining 14 percent. As the pharmaceutical sector expands in Mexico, there may be a growing interest in microbiome-based therapeutics for various diseases and conditions. Hence, the increasing investments in the healthcare sector and the rising pharmaceutical industry in the region are propelling the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
By Application
- Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
- Research Application
- Reagents & Kits
- Instruments
- Fecal
- Saliva
- Skin
- Others
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Others
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
123 Pages
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Microbiome Diagnostics Market, by Application
- 1.4.2 North America Microbiome Diagnostics Market, by Product
- 1.4.3 North America Microbiome Diagnostics Market, by Sample
- 1.4.4 North America Microbiome Diagnostics Market, by Technology
- 1.4.5 North America Microbiome Diagnostics Market, by End User
- 1.4.6 North America Microbiome Diagnostics Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Opportunities
- 3.2.3 Market Restraints
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Strategies Deployed in Microbiome Diagnostics Market
- Chapter 5. North America Microbiome Diagnostics Market by Application
- 5.1 North America Disease Diagnostics Market by Region
- 5.2 North America Microbiome Diagnostics Market by Disease Diagnostics Type
- 5.2.1 North America Gastrointestinal Disorders Market by Country
- 5.2.2 North America Metabolic Diseases Market by Country
- 5.2.3 North America Others Market by Country
- 5.3 North America Research Application Market by Region
- Chapter 6. North America Microbiome Diagnostics Market by Product
- 6.1 North America Reagents & Kits Market by Country
- 6.2 North America Instruments Market by Country
- Chapter 7. North America Microbiome Diagnostics Market by Sample
- 7.1 North America Fecal Market by Country
- 7.2 North America Saliva Market by Country
- 7.3 North America Skin Market by Country
- 7.4 North America Others Market by Country
- Chapter 8. North America Microbiome Diagnostics Market by Technology
- 8.1 North America 16S rRNA Sequencing Market by Country
- 8.2 North America Shot Gun Metagenomics Market by Country
- 8.3 North America Metatranscriptomics Market by Country
- 8.4 North America Others Market by Country
- Chapter 9. North America Microbiome Diagnostics Market by End User
- 9.1 North America Hospitals Market by Country
- 9.2 North America Academic & Research Institutes Market by Country
- 9.3 North America Biotechnology & Pharmaceutical Companies Market by Country
- Chapter 10. North America Microbiome Diagnostics Market by Country
- 10.1 US Microbiome Diagnostics Market
- 10.1.1 US Microbiome Diagnostics Market by Application
- 10.1.1.1 US Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.1.2 US Microbiome Diagnostics Market by Product
- 10.1.3 US Microbiome Diagnostics Market by Sample
- 10.1.4 US Microbiome Diagnostics Market by Technology
- 10.1.5 US Microbiome Diagnostics Market by End User
- 10.2 Canada Microbiome Diagnostics Market
- 10.2.1 Canada Microbiome Diagnostics Market by Application
- 10.2.1.1 Canada Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.2.2 Canada Microbiome Diagnostics Market by Product
- 10.2.3 Canada Microbiome Diagnostics Market by Sample
- 10.2.4 Canada Microbiome Diagnostics Market by Technology
- 10.2.5 Canada Microbiome Diagnostics Market by End User
- 10.3 Mexico Microbiome Diagnostics Market
- 10.3.1 Mexico Microbiome Diagnostics Market by Application
- 10.3.1.1 Mexico Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.3.2 Mexico Microbiome Diagnostics Market by Product
- 10.3.3 Mexico Microbiome Diagnostics Market by Sample
- 10.3.4 Mexico Microbiome Diagnostics Market by Technology
- 10.3.5 Mexico Microbiome Diagnostics Market by End User
- 10.4 Rest of North America Microbiome Diagnostics Market
- 10.4.1 Rest of North America Microbiome Diagnostics Market by Application
- 10.4.1.1 Rest of North America Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.4.2 Rest of North America Microbiome Diagnostics Market by Product
- 10.4.3 Rest of North America Microbiome Diagnostics Market by Sample
- 10.4.4 Rest of North America Microbiome Diagnostics Market by Technology
- 10.4.5 Rest of North America Microbiome Diagnostics Market by End User
- Chapter 11. Company Profiles
- 11.1 Illumina, Inc.
- 11.1.1 Company Overview
- 11.1.2 Financial Analysis
- 11.1.3 Regional Analysis
- 11.1.4 Research & Development Expense
- 11.1.5 Recent strategies and developments:
- 11.1.5.1 Partnerships, Collaborations, and Agreements:
- 11.1.6 SWOT Analysis
- 11.2 Becton, Dickinson, and Company
- 11.2.1 Company Overview
- 11.2.2 Financial Analysis
- 11.2.3 Segmental and Regional Analysis
- 11.2.4 Research & Development Expense
- 11.2.5 Recent strategies and developments:
- 11.2.5.1 Product Launches and Product Expansions:
- 11.2.5.2 Trails and Approvals:
- 11.2.6 SWOT Analysis
- 11.3 Genetic Analysis AS
- 11.3.1 Company Overview
- 11.3.2 Financial Analysis
- 11.3.3 Regional Analysis
- 11.3.4 Recent strategies and developments:
- 11.3.4.1 Partnerships, Collaborations, and Agreements:
- 11.4 Microba Life Sciences Limited
- 11.4.1 Company Overview
- 11.4.2 Financial Analysis
- 11.4.3 Regional Analysis
- 11.4.4 Research & Development Expenses
- 11.4.5 Recent strategies and developments:
- 11.4.5.1 Partnerships, Collaborations, and Agreements:
- 11.4.5.2 Product Launches and Product Expansions:
- 11.5 BioMe Oxford Ltd
- 11.5.1 Company Overview
- 11.5.2 Recent strategies and developments:
- 11.5.2.1 Partnerships, Collaborations, and Agreements:
- 11.6 Viome Life Sciences, Inc.
- 11.6.1 Company Overview
- 11.6.2 Recent strategies and developments:
- 11.6.2.1 Product Launches and Product Expansions:
- 11.6.2.2 Acquisition and Mergers:
- 11.7 GoodGut S.L.U. (HIPRA, S.A.)
- 11.7.1 Company Overview
- 11.8 Sun Genomics
- 11.8.1 Company Overview
- 11.9 Origin Sciences Limited
- 11.9.1 Company Overview
- 11.10. Decode Age
- 11.10.1 Company Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.